AbbVie (ABBV) News Today

AbbVie Inc. (NYSE:ABBV) shares are trading lower today after analysts at William Blair trimmed both Q2 and full-year EPS forecasts, although recent pipeline deals and a favorable court ruling offer some offsetting support.

• Positive Sentiment: AbbVie expanded its oncology pipeline by licensing IGI’s myeloma candidate ISB 2001 under a deal worth up to $1.9 billion. AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+
• Positive Sentiment: A federal judge dismissed AbbVie’s lawsuit over Missouri’s 340B law, removing a potential legal overhang. Federal judge tosses AbbVie lawsuit over Missouri 340B law
• Positive Sentiment: Technical analysts point to a “golden cross” in AbbVie’s chart—a bullish signal suggesting further upside. Here's How to Play AbbVie Stock as it Reaches Golden Cross
• Neutral Sentiment: AbbVie’s “Week of Possibilities” event united employees across Asia for community impact, underscoring its CSR focus. AbbVie's 10th 'Week of Possibilities' Unites Employees Across Asia for Community Impact
• Neutral Sentiment: AbbVie was highlighted as one of “3 Stocks With Excellent Upside Potential” by WallStreetZen. 3 Stocks With Excellent Upside Potential
• Neutral Sentiment: MarketBeat included AbbVie in its “Best Biotech Stocks To Research” list for July 15th. Best Biotech Stocks To Research - July 15th
• Neutral Sentiment: Glenmark’s R&D arm said it’s now self-sufficient for years after a landmark AbbVie collaboration. Glenn Saldanha: Glenmark's R&D unit now self-sufficient for years after landmark AbbVie deal
• Negative Sentiment: William Blair cut its Q2 2025 EPS forecast for AbbVie to $2.88, down from $3.27. William Blair Has Pessimistic Outlook of AbbVie Q2 Earnings
• Negative Sentiment: William Blair also lowered its full-year 2025 EPS estimate to $11.82 from $12.21. William Blair Has Pessimistic View of AbbVie FY2025 Earnings